Ardena Secures Full GMP Approval for Expanded Nanomedicine Facility in Oss, Netherlands

" Ardena, a leading CDMO, has received full GMP approval for its advanced nanomedicine facility in Oss. This €20 million investment, featuring state...

November 20, 2024 | Wednesday | News
Adragos Pharma Expands Production with €13 Million Investment in New Ampoule Filling Line, Boosting Capacity by 30%

Adragos Pharma, a leading Contract Development & Manufacturing Organisation (CDMO), has significantly enhanced its production capabilities with the com...

November 13, 2024 | Wednesday | News
Aulisa® Medical USA Launches Flexible Leasing Options for Advanced Continuous Vital Sign Monitoring Solutions

Aulisa® Medical USA, Inc., a leader in FDA-cleared, wearable, wireless continuous vital sign monitoring technology, proudly announces the launch o...

November 08, 2024 | Friday | News
GHIT Fund Commits JPY 578 Million to Pioneering Projects Targeting Malaria and Neglected Tropical Diseases

The Global Health Innovative Technology (GHIT) Fund announced a total investment of approximately JPY 578 million (USD 4.0 million1) in four...

November 07, 2024 | Thursday | News
Acadia Pharmaceuticals to Sell Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority...

November 06, 2024 | Wednesday | News
Bionomics Secures AUS$1M Milestone Payment from Carina Biotech for Progress in Australia’s Oncology Program

Bionomics , a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from s...

November 05, 2024 | Tuesday | News
Syndax Pharmaceuticals Secures $350 Million Synthetic Royalty Funding Agreement with Royalty Pharma for Niktimvo™

Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) announced that Syndax has entered into a $350 million synth...

November 05, 2024 | Tuesday | News
Ate Therapeutics Grants 16,400 Restricted Stock Units to New Employees

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripot...

November 04, 2024 | Monday | News
Biogen and Neomorph Forge Collaboration to Develop Molecular Glue Degraders for Neurological and Immunological Diseases

 Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority ta...

October 30, 2024 | Wednesday | News
GSK Acquires CMG1A46 from Chimagen for $300 Million to Target B Cell-Driven Autoimmune Diseases

GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a c...

October 30, 2024 | Wednesday | News
MilliporeSigma Rolls Out €70 Million Expansion to Transform St. Louis into a Hub for Advanced ADC Manufacturing and Biopharma Innovation

Merck, a leading science and technology company, announced a € 70 million expansion of its ADC manufacturing capabilities and capacity at its Bioconju...

October 30, 2024 | Wednesday | News
PL Developments Secures FDA Approval for Omeprazole OTC and Successfully Refinances Corporate Debt

PL Developments (PLD), a leader in the development, manufacturing, packaging, and distribution of consumer healthcare products, announced two significant m...

October 29, 2024 | Tuesday | News
AbbVie and Gedeon Richter Forge New Agreement to Explore Treatments for Neuropsychiatric Disorders

 AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') announced a new discovery, co-development and license agreement to advance novel targets for ...

October 25, 2024 | Friday | News
Sanofi and CD&R Announce Exclusive Negotiations for 50% Stake in Opella, Poised to Create Global Consumer Healthcare Leader

 Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. S...

October 22, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close